USPTO Form 1449 U.S. Department of Commerce Patent and Tradence Office INFORMATION DISCLOSURE STATEMENT			Attorney Docket No. 27053/2062		Serial No. 10/674,148		
HADENIATIO	V DISCLOSURE STAT	EMENT	Applicant(s):. Hayle	y Zen			_
			Filing Date: September 29, 2003			Group: Not Yet Assigned	
U.S. PATENT I	OCUMENTS						
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Subclass Filing Date (if appropriate)	
		<u> </u>			<u> </u>		· · · · · · · · · · · · · · · · · · ·
FOREIGN PAT	ENT DOCUMENTS						
Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO
OTHER DOCU	MENTS (including Autl	nor, Title, Date, Pert	inent Pages, etc.)		•		
A0 1.	Wender, P.A. et al., (1998), "The chemistry-medicine continuum: Synthetic, computer, spectroscopic and biological studies on new chemotherapeutic leads", <i>Pure. & Appl. Chem.</i> , 70(3):539-546.						
A0 2.	Lee, J. et al., (1996), "Conformationally Constrained Analogues of Diacylglycerol. 11 Ultrapotent Protein Kinase C Ligands Based on a Chiral 5-Disubstituted Tetrahydro-2-furanon Templote". J. Mod. Char., 20:20, 25						
	Template", J. Med. Chem., 39:29-35. Lee, J. et al., (1996), "Conformationally Constrained Analogues of Diacylglycerol. 12. Ultrapotent Protein Kinase C Ligands Based on a Chiral 4,4-Disubstituted Heptono-1,4-lactone Template", J. Med. Chem., 39:36-45.						
AU 3.	lactone Template";	J. Med. Chem., 3	9:30-43.				